SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-002272
Filing Date
2024-01-16
Accepted
2024-01-12 18:02:54
Documents
12
Period of Report
2024-01-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43441
  Complete submission text file 0001493152-24-002272.txt   212817

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtro-20240110.xsd EX-101.SCH 3033
3 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtro-20240110_lab.xml EX-101.LAB 34240
4 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtro-20240110_pre.xml EX-101.PRE 22371
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3042
Mailing Address 3200 CHERRY CREEK DRIVE SOUTH SUITE 410 DENVER CO 80209
Business Address 3200 CHERRY CREEK DRIVE SOUTH SUITE 410 DENVER CO 80209 8558487627
Vitro Biopharma, Inc. (Filer) CIK: 0000793171 (see all company filings)

IRS No.: 841012042 | State of Incorp.: NV | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-41766 | Film No.: 24533094
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)